News | January 20, 2026
Syngene locks in Bristol Myers Squibb alliance through 2035
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
India plays a critical role in Bristol Myers Squibb’s global strategy
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
The company is excluding data from the affected sites to maintain the study's integrity
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
The offering is expected to close on November 10, 2025, subject to customary closing conditions
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Subscribe To Our Newsletter & Stay Updated
